key: cord-0875228-06wbit2a authors: Sanjay, Srinivasan; Kawali, Ankush title: Comment on: COVID-19 vaccine-associated reactivation of uveitis date: 2022-01-03 journal: Indian J Ophthalmol DOI: 10.4103/ijo.ijo_2741_21 sha: e16437d5353016a52b02193bd8c1d952d4ee4c0a doc_id: 875228 cord_uid: 06wbit2a nan We read with interest the article by Jain and Kalamkar. [1] They have described a patient who had bilateral uveitis in 2012 and had no relapse since then till the present episode. We would like to share two instances that are related to the present case report. [2, 3] Our patient, who had unilateral granulomatous uveitis and intermediate uveitis, had a relapse of his anterior uveitis after coronavirus disease 19 . In this instance, the possible role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) would have been a trigger. This may be similar to the case reported by Jain and Kalamkar, [1] where the anterior uveitis recurred after the COVID-19 vaccine. Our patient had been investigated for all possible causes of anterior uveitis, and all the tests were negative. The only positive finding was raised COVID-19 IgG antibodies. [2] Second, another patient who had HLA-B27-related anterior uveitis who stopped his immunosuppression and adalimumab during lockdown of 8 weeks [3, 4] had developed COVID-19 albeit with mild symptoms; however, he developed recurrence of unilateral non-granulomatous anterior uveitis 3 weeks later. It is possible that there might have been a recurrence due to cessation of his immunosuppression during the lockdown. He was free of eye symptoms for at least a month or more after stopping medication and during his admission for COVID-19. His eye symptoms started 3 weeks after discharge from the hospital. Both our patients were not vaccinated against COVID-19. [1] highlighted the fact that this could be possible due to the COVID-19 vaccine. Based on the existing evidence in medical literature, it is difficult to find an association or causal factor for the COVID-19 vaccine. Moreover, the authors could add the Naranjo scale [5] for their patients. The adverse drug reaction (ADR) probability scale was developed in 1991 by Naranjo et al. from the University of Toronto and is often referred to as the Naranjo scale. This scale was developed to help standardize the assessment of causality for all adverse drug reactions. The scale was also designed for use in controlled trials and registration studies of new medications, rather than in routine clinical practice. Nevertheless, it is simple to apply and widely used. The adjuvants majorly effective in some genetically predisposed patients can cause an inflammatory syndrome. [6] There is also a possible role of adjuvants, mostly aluminum salts used in the vaccines that act as immune-stimulatory molecules, which broaden the immune response. [7] The innate immunity stimulation occurs through endosolic or cytoplasmic nucleic acid receptors. [8] Immune response following immunization may be triggered in autoimmune diseases, particularly those connective tissues diseases that are associated with an altered nucleic acid metabolism and processing. [9, 10] The pathogenesis of uveitis should have been discussed by the authors. We cannot rule out the possibility of either COVID-19 or COVID-19 vaccination acting as a trigger for new-onset ocular inflammation in our reported cases or the present case report. [2, 3, 11, 12] Post COVID-19 patients can have a dysfunctional immune system causing unregulated production of cytokines such as interleukin-6 (IL-6), IL-1b, IFN-g, MCP-1, IP-10, IL-4, and IL-10, leading to a downward spiral of immune-mediated end-organ damage. [13, 14] This may also cause ocular manifestations such as uveitis. COVID-19 vaccine-associated reactivation of uveitis Post coronavirus disease (COVID-19) reactivation of a quiescent unilateral anterior uveitis Lockdown effects on a patient receiving immunosuppression for unilateral HLA-B27 associated uveitis during COVID-19 pandemic Impact of COVID-19 on a tertiary eye hospital LiverTox: Clinical and Research Information on Drug-Induced Liver Injury Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; A systematic review Ocular adverse events after COVID-19 vaccination Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination COVID-19 vaccines: Modes of immune activation and future challenges Post corona virus Disease-19 (COVID-19): Hyper inflammatory syndrome-associated bilateral anterior uveitis and multifocal serous retinopathy secondary to steroids Recurrent bilateral idiopathic anterior uveitis with vitritis post Coronavirus Disease 2019 infection Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China The immunology of COVID-19: Is immune modulation an option for treatment? Dear Editor, With great interest, I went through the article titled "Central retinal vein occlusion secondary to varicella zoster retinal vasculitis in an immunocompetent individual during the COVID-19 pandemic -A case report" by Sarpangala et al. [1] The authors have managed a tricky case in which multiple etiologies had to be ruled out. I have a few observations. The authors have mentioned that there was clinical improvement 3 days following institution of systemic anti-viral therapy. However, in the clinical fundus photograph provided, 3 days following therapy, it seems as if the vascular sheathing along the superotemporal vein has actually increased (worsened) following anti-viral therapy. It would be good to know the duration between initial presentation and institution of systemic therapy. A longer duration between initial presentation and start of therapy might have led to an increase in the vascular sheathing. It will also be interesting to know if there was an increase in visual acuity and decrease in vitreous haze 3 days after starting anti-viral therapy.Ocular involvement in sarcoidosis is present in 80% of the cases and is frequently manifested before the diagnosis of systemic disease. [2] Posterior segment involvement in sarcoidosis can take the form of retinal vasculitis, perivenous infiltrates with characteristic candle wax drippings, choroiditis patches, and optic nerve granuloma. Absence of characteristic sarcoid lesions does not rule out ocular sarcoidosis. The definitive diagnosis of ocular sarcoidosis is based on biopsy-proven lesions compatible with clinical signs of uveitis. [2] Investigations supportive of ocular sarcoidosis include raised serum angiotensin-converting enzyme (ACE)/lysozyme levels, chest X-ray or high-resolution computed tomography suggestive of bilateral perihilar lymphadenopathy, abnormal liver enzyme tests, and negative tuberculin test in a BCG-vaccinated patient. [2] The present case had raised serum ACE levels. Other laboratory tests supportive of ocular sarcoidosis could have been performed before ruling it out as a possible etiology.